INDP Stock Overview
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Indaptus Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.01 |
| 52 Week High | US$4.08 |
| 52 Week Low | US$1.56 |
| Beta | 1.22 |
| 1 Month Change | -14.32% |
| 3 Month Change | 17.94% |
| 1 Year Change | -19.48% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -77.40% |
Recent News & Updates
Recent updates
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?
Mar 27
Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?
Aug 15Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45
Aug 08Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications
Sep 29Shareholder Returns
| INDP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.0% | 0.5% | -0.7% |
| 1Y | -19.5% | 1.2% | 22.8% |
Return vs Industry: INDP underperformed the US Biotechs industry which returned 1.2% over the past year.
Return vs Market: INDP underperformed the US Market which returned 22.8% over the past year.
Price Volatility
| INDP volatility | |
|---|---|
| INDP Average Weekly Movement | 13.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INDP's share price has been volatile over the past 3 months.
Volatility Over Time: INDP's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Jeff Meckler | indaptusrx.com |
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.
Indaptus Therapeutics, Inc. Fundamentals Summary
| INDP fundamental statistics | |
|---|---|
| Market cap | US$17.30m |
| Earnings (TTM) | -US$15.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.1x
P/E RatioIs INDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INDP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$15.42m |
| Earnings | -US$15.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.81 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did INDP perform over the long term?
See historical performance and comparison